查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1300977

美国大麻素市场规模、份额和趋势分析报告：按产品类型、按应用、细分趋势：2023-2030

U.S. Cannabinoids Market Size, Share & Trends Analysis Report By Product Type (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabigerol (CBG)), By Application (Inflammation, Pain Management), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 86 Pages | 商品交期: 2-10个工作天内

价格

美国大麻素市场增长和趋势

美国大麻素市场规模预计到 2030 年将达到 603.6 亿美元，2023 年至 2030 年復合年增长率为 15.3%。

越来越多的消费者选择分离的大麻素产品，在增加临床研究以了解和扩大与大麻素相关的应用的帮助下，推动了美国整体市场的增长。

大麻素日益增加的健康益处在许多研究和临床试验中都显示出积极的结果，导致 CBD 等大麻素在多种疾病中的使用范围扩大。 此外，医疗保健专业人员针对某些健康状况越来越多地开出大麻素（尤其是 CBD）处方，这有助于进一步增加对这些产品的需求。 例如，2020 年对美国皮肤科医生的一项调查发现，7,176 名受访者中约 91% 对向患者开基于 CBD 的产品持积极态度。 然而，不推荐大麻用于医疗用途的主要原因是缺乏与大麻素相关的知识和限制。

此外，许多研究表明，使用大麻对减少化疗引起的噁心和呕吐具有积极作用。 癌症治疗的另一个副作用是化疗引起的周围神经病变（CIPN）。 多项临床试验和研发正在进行中，以开发基于大麻的药物来治疗 CIPN。 例如，2022年6月，梅奥诊所与国家癌症研究所共同发起了一项评估外用CBD在CIPN症状管理中的功效的研究，该研究预计将于2024年4月完成。

此外，领先的公司正在合作开发与大麻素相关的新颖应用程序，以满足不断增长的需求，使公司能够获得有助于改善其供应炼和产品开发的资源。我可以。 此外，许多公司还注重产品发布，以扩大产品组合。 例如，2023年2月，SAVO Cannabis 获得了 Brightsmith Capital Partners 的资金，用于开发新的大麻种植基因设施。

美国大麻素市场报告亮点

  • 2022 年，大麻二酚 (CBD) 细分市场占据最大份额，达到 26.7%。 这是因为 CBD 不仅用于药物治疗，还用于运动恢復、健康、美容和皮肤护理等活动。
  • 由于慢性疼痛的患病率不断增加以及大麻素相关的镇痛特性，预计疼痛管理领域将以最快的复合年增长率增长。
  • 由于神经系统疾病患病率上升以及与使用大麻素治疗神经系统疾病相关的研究不断增加，神经系统疾病细分市场到 2022 年将占据 22.1% 的巨大市场份额。
  • 随着消费者寻求含有这些化合物的新型创新产品，次要大麻素的供应量不断增加预计将推动整个市场的增长。
  • 主导市场的主要公司有 Mile High Labs、Global Cannabinoids、GenCanna、High Purity Natural Products、Rhizo Sciences、CBD Inc.、LaurelCrest、Fresh Bros Hemp Company、Precision Plant Molecules、BulKanna、Zero Point Extraction, LLC 等。

内容

第一章调查方法及范围

  • 市场细分和范围
  • 调查方法
  • 信息获取
  • 信息或数据分析
  • 市场形成和验证
  • 型号详细信息
  • 调查假设
  • 辅助信息列表
  • 缩写列表
  • 目的

第 2 章执行摘要

  • 市场前景
  • 分部展望
  • 竞争考虑因素

第 3 章美国大麻素市场变量、趋势和范围

  • 市场体系展望
    • 家长市场
  • 监管场景
  • 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
  • 美国大麻素市场分析工具
    • 美国大麻素市场 - PESTLE 分析
    • 美国大麻素市场 - 波特的分析
  • 新型冠状病毒的影响分析
  • 供应链分析
    • 供应链分析 - CBD 消费保健品
  • 产品采用模式分析
    • 大麻二酚 (CBD)
    • 四氢大麻酚 (THC)
    • 大麻酚 (CBN)
    • 大麻二酚酸 (CBDA)
    • 其他
  • 生物合成大麻素
  • 美国次要大麻素市场的未来趋势
    • 产品多元化：
    • 提高微量大麻素的可用性：
    • 更多品牌进入市场：
    • 对自然疗法的需求不断增长：
  • TAM-SAM-SOM 分析
  • 行业 KOL 成绩单
  • 主要受访者的主要分析

第 4 章美国大麻素市场细分分析：按产品类型划分，2018-2030 年

  • 定义和范围
  • 2022 年和 2030 年产品类型市场份额分析
  • 细分仪表板
  • 2018-2030 年美国大麻素市场（按产品类型）
  • 2018-2030 年市场规模、预测和趋势分析
    • 大麻二酚 (CBD)
    • 四氢大麻酚 (THC)
    • 大麻酚 (CBN)
    • 大麻二酚酸 (CBGA)
    • 大麻酚 (CBG)
    • 大麻环烯 (CBC)
    • 四氢大麻二酚 (THCV)
    • 其他

第五章美国大麻素市场细分分析：按应用划分，2018-2030

  • 定义和范围
  • 2022 年和 2030 年应用市场份额分析
  • 细分仪表板
  • 2018-2030 年美国大麻素市场（按应用）
  • 2018-2030 年市场规模、预测和趋势分析
    • 炎症
    • 疼痛管理
    • 神经系统疾病
    • 癌症
    • 其他

第 6 章。美国大麻素市场 - 竞争分析

  • 主要市场进入者的最新趋势和影响分析
  • 公司分类
  • 企业市场分析
  • 公司简介
    • Mile High Labs
    • Global Cannabinoids
    • GenCanna
    • CBD Inc.
    • Precision Plant Molecules
    • Rhizo Sciences
    • LaurelCrest
    • Fresh Bros Hemp Company
    • BulKanna
    • High-Purity Natural Products
    • Zero Point Extraction, LLC
Product Code: GVR-4-68039-255-9

U.S. Cannabinoids Market Growth & Trends

The U.S. cannabinoids market size is expected to reach USD 60.36 billion by 2030, registering a CAGR of 15.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing number of consumers opting for isolated cannabinoid products aided by growing clinical studies to understand and expand applications associated with cannabinoids is driving the growth of the overall market in the U.S. Moreover, the growing new entrants in the market further leading to the expansion of the availability of products is propelling this growth.

The growing benefits associated with cannabinoids on health have been showing affirmative results in a number of research and clinical trials, which has led to expansion in the use of cannabinoids, such as CBD, for various conditions, which in turn has increased the demand for cannabinoid products in the country. In addition, the rising prescription of cannabinoids by medical practitioners, mainly CBD, for certain health conditions has further helped in increasing the demand for these products. For instance, according to a survey of dermatologists carried out in the U.S., in 2020, out of 7176 respondents, around 91% were affirmative about prescribing CBD-based products to their patients. However, the major reason for the non-recommendation of cannabis for medical use was due to the lack of or limited knowledge associated with cannabinoids.

Moreover, many studies suggest affirmative results of cannabis use in reducing the instances of nausea and vomiting caused by chemotherapy. Some other adverse effects of cancer treatment are Chemotherapy-induced Peripheral Neuropathy (CIPN). Multiple clinical trials and research studies are ongoing to develop cannabis-based medication for treating CIPN. For instance, in June 2022, a study to assess the efficacy of topical CBD in managing symptoms of CIPN was sponsored by Mayo Clinic in collaboration with National Cancer Institute, and this study is expected to be completed by April 2024.

Furthermore, major companies are collaborating for the development of novel applications linked with cannabinoids to meet the rising demand which enables businesses to use their resources to help with improvements in supply chain and product development. Moreover, a number of players are also focusing on product launches to expand their product portfolio. For instance, in February 2023, SAVO Cannabis received funding from Brightsmith Capital Partners for the development of new cannabis cultivation genetic facility focusing on the development of cannabis for specific effects majorly targeting body and mind for life-enhancing purposes.

U.S. Cannabinoids Market Report Highlights

  • In 2022, Cannabidiol (CBD) segment held the largest share of 26.7% owing to the adoption of CBD not only in medication but also in activities such as sports recovery, wellness, beauty, and skincare
  • Pain management segment is anticipated to grow at the fastest CAGR due to the increasing prevalence of chronic pain and analgesic properties associated with cannabinoids
  • Neurological disorders segment accounted for a significant market share of 22.1% in 2022 due to the growing research associated with the use of cannabinoids in neurological conditions with the increasing prevalence of the conditions
  • The increasing availability of minor cannabinoids is expected to drive the growth of the overall market as consumers seek out new and innovative products containing these compounds
  • Key players dominating the market include Mile High Labs; Global Cannabinoids; GenCanna; High Purity Natural Products; Rhizo Sciences; CBD Inc.; LaurelCrest; Fresh Bros Hemp Company; Precision Plant Molecules; BulKanna; Zero Point Extraction, LLC

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 U.S. Cannabinoids Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market
  • 3.2 Regulatory Scenario
  • 3.3 Market Dynamics
    • 3.3.1 Market drivers analysis
      • 3.3.1.1 Growing number of new entrants in the market leading to expansion in product availability
      • 3.3.1.2 Increasing number of consumers opting for isolated cannabinoid products
      • 3.3.1.3 Growing number of clinical studies on the use of cannabinoids for specific applications
      • 3.3.1.4 Rising awareness about cannabinoid products and their use in health and wellness
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 High price of cannabinoids-based products
      • 3.3.2.2 Expensive extraction processes for cannabinoids
      • 3.3.2.3 Absence of definite regulatory framework for minor cannabinoids
      • 3.3.2.4 Limited research is hindering the growth of the cannabinoids market
  • 3.4 U.S. Cannabinoids Market Analysis Tools
    • 3.4.1 U.S. Cannabinoids Market - PESTLE Analysis
    • 3.4.2 U.S. Cannabinoids Market - PORTER'S Analysis
  • 3.5 COVID Impact Analysis
  • 3.6 Supply Chain Analysis
    • 3.6.1 Supply Chain Analysis - CBD Consumer Health Product
  • 3.7 Product Adoption Pattern Analysis
    • 3.7.1 Cannabidiol (CBD)
    • 3.7.2 Tetrahydrocannabinol (THC)
    • 3.7.3 Cannabinol (CBN)
    • 3.7.4 Cannabidiolic Acid (CBDA)
    • 3.7.5 Others
      • 3.7.5.1 Cannabigerol (CBG)
      • 3.7.5.2 Cannabichromene (CBC)
  • 3.8 Biosynthetic Cannabinoids
  • 3.9 Upcoming Trends in U.S. Minor Cannabinoids Market
    • 3.9.1 Diversification Of Products:
    • 3.9.2 Increased Availability Of Minor Cannabinoids:
    • 3.9.3 More Brands Entering The Market:
    • 3.9.4 Growing Demand For Natural Remedies:
  • 3.10 TAM-SAM-SOM Analysis
  • 3.11 Transcript of an industry KOL
  • 3.12 Key Analysis from the Primary Respondents

Chapter 4 U.S. Cannabinoids Market Segment Analysis, By Product Type, 2018 - 2030 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Product Type Market Share Analysis, 2022 & 2030
  • 4.3 Segment Dashboard
  • 4.4 U.S. Cannabinoids Market, by Product Type, 2018 to 2030
  • 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.5.1 Cannabidiol (CBD)
      • 4.5.1.1 Cannabidiol (CBD) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.2 Tetrahydrocannabinol (THC)
      • 4.5.2.1 Tetrahydrocannabinol (THC) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.3 Cannabinol (CBN)
      • 4.5.3.1 Cannabinol (CBN) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.4 Cannabigerolic Acid (CBGA)
      • 4.5.4.1 Cannabigerolic acid (CBGA) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.5 Cannabigerol (CBG)
      • 4.5.5.1 Cannabigerol (CBG) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.6 Cannabichromene (CBC)
      • 4.5.6.1 Cannabichromene (CBC) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.7 Tetrahydrocannabivarin (THCV)
      • 4.5.7.1 Tetrahydrocannabivarin (THCV) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.8 Others
      • 4.5.8.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5 U.S. Cannabinoids Market Segment Analysis, By Application 2018 - 2030 (USD Million)

  • 5.1 Definition and Scope
  • 5.2 Application Market Share Analysis, 2022 & 2030
  • 5.3 Segment Dashboard
  • 5.4 U.S. Cannabinoids Market, by Application, 2018 to 2030
  • 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.5.1 Inflammation
      • 5.5.1.1 Inflammation market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.2 Pain Management
      • 5.5.2.1 Pain management market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.3 Neurological Disorders
      • 5.5.3.1 Neurological disorders market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.4 Cancer
      • 5.5.4.1 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.5 Others
      • 5.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 U.S. Cannabinoids Market - Competitive Analysis

  • 6.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 6.1.2 Heat map analysis
    • 6.1.3 Major Deals and Strategic Alliances Analysis
      • 6.1.3.1 Joint Ventures
      • 6.1.3.2 Licensing Agreements
      • 6.1.3.3 Product Launches
  • 6.2 Company Categorization
    • 6.2.1 Innovators
    • 6.2.2 Market Leaders
  • 6.3 Company Market Position Analysis
  • 6.4 Company Profiles
    • 6.4.1 Mile High Labs
      • 6.4.1.1 Company overview
      • 6.4.1.2 Financial performance
      • 6.4.1.3 Product benchmarking
      • 6.4.1.4 Strategic Initiatives
    • 6.4.2 Global Cannabinoids
      • 6.4.2.1 Company overview
      • 6.4.2.2 Financial performance
      • 6.4.2.3 Product benchmarking
      • 6.4.2.4 Strategic Initiatives
    • 6.4.3 GenCanna
      • 6.4.3.1 Company overview
      • 6.4.3.2 Financial performance
      • 6.4.3.3 Product benchmarking
      • 6.4.3.4 Strategic Initiatives
    • 6.4.4 CBD Inc.
      • 6.4.4.1 Company overview
      • 6.4.4.2 Financial performance
      • 6.4.4.3 Product benchmarking
      • 6.4.4.4 Strategic Initiatives
    • 6.4.5 Precision Plant Molecules
      • 6.4.5.1 Company overview
      • 6.4.5.2 Financial performance
      • 6.4.5.3 Product benchmarking
      • 6.4.5.4 Strategic Initiatives
    • 6.4.6 Rhizo Sciences
      • 6.4.6.1 Company overview
      • 6.4.6.2 Financial performance
      • 6.4.6.3 Product benchmarking
      • 6.4.6.4 Strategic Initiatives
    • 6.4.7 LaurelCrest
      • 6.4.7.1 Company overview
      • 6.4.7.2 Financial performance
      • 6.4.7.3 Product benchmarking
      • 6.4.7.4 Strategic initiatives
    • 6.4.8 Fresh Bros Hemp Company
      • 6.4.8.1 Company overview
      • 6.4.8.2 Financial performance
      • 6.4.8.3 Product benchmarking
      • 6.4.8.4 Strategic initiatives
    • 6.4.9 BulKanna
      • 6.4.9.1 Company overview
      • 6.4.9.2 Financial performance
      • 6.4.9.3 Product benchmarking
      • 6.4.9.4 Strategic initiatives
    • 6.4.10 High-Purity Natural Products
      • 6.4.10.1 Company overview
      • 6.4.10.2 Financial performance
      • 6.4.10.3 Product benchmarking
      • 6.4.10.4 Strategic initiatives
    • 6.4.11 Zero Point Extraction, LLC
      • 6.4.11.1 Company overview
      • 6.4.11.2 Financial performance
      • 6.4.11.3 Product benchmarking
      • 6.4.11.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Key companies undergoing collaboration
  • Table 4 Key companies undergoing partnership
  • Table 5 Key companies undergoing product launch
  • Table 6 Key companies undergoing new products/services

List of Figures

  • Fig. 1 U.S. cannabinoids market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook (2022)
  • Fig. 10 Strategy framework
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 U.S. cannabinoids market: Product type movement analysis
  • Fig. 17 U.S. cannabinoids market: Product type segment dashboard
  • Fig. 18 U.S. cannabinoids market product type outlook: Key takeaways
  • Fig. 19 Tetrahydrocannabinol (THC) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Cannabidiol (CBD) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Cannabigerol (CBG) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Cannabichromene (CBC) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Cannabinol (CBN) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Tetrahydrocannabivarin (THCV) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Cannabigerolic Acid (CBGA) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. cannabinoids market: Application movement analysis
  • Fig. 28 U.S. cannabinoids market: Application segment dashboard
  • Fig. 29 U.S. cannabinoids market Application outlook: Key takeaways
  • Fig. 30 Inflammation U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Pain Management U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Neurological Disorders U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Cancer U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Heat map analysis
  • Fig. 36 Market differentiators